Skip to main content
Cooper to pay $1.1B for Teva's intrauterine contraceptive device business
9/13/2017

The Cooper Cos., a US medical device company, reached a $1.1 billion deal to acquire the ParaGard intrauterine contraceptive device business from Teva Pharmaceutical Industries. The transaction, which is part of Teva's planned divestment of its women's health unit, includes the device manufacturing facility in Buffalo, N.Y., and is expected to be completed by year-end.

Full Story: